Jellatech, headquartered in Raleigh, NC, is a biotechnology startup founded in 2020. Their mission is encapsulated in their slogan: "Real Collagen. No Compromise." This B2B company innovatively produces human proteins through cell-based technology, focusing initially on Type I collagen. By overcoming the complexity of protein production on a commercial scale, Jellatech is poised to make significant impacts in tissue regeneration, injectable aesthetics, cell and gene therapy, among other therapeutic fields.
The market for tissue-extracted bovine and porcine collagen for biomedical use is projected to exceed $2.4 billion by 2032. However, the company's advancements point to a far larger opportunity. The total addressable market for human collagen could reach between $100-150 billion soon.
In its latest development, Jellatech closed a $3.50 million Seed Round investment on 06 September 2023. This funding further underlines its potential to transform global healthcare markets by providing a consistent supply of bio-identical human proteins.